©2002 General Telometrics
Corporation. All rights reserved.

Anti-Cancer Pharmaceuticals

Making life better, one discovery at a time

Medicine has long known about mitomycin and pikromycin, two relatively weak and ineffective anti-tumor compounds. Though their amino acid sequences show that they are designed to combat cancers, they are incapable of completing their job. Fortunately, through modern pathway ordering technology, General Telometrics has succeeded in improving the efficiency of these two drugs one thousand-fold. This is still a fraction of the strength necessary to make these drugs marketable and useful, but with more novel variations discovered every month, there is hope that these two pharmocological products will soon be available for cancer patients. Our strongest drugs currently are MitomycinJ, novel MitomycinD, and PikromycinM. There is a chance that the FDA may approve novel MitomycinD for human trials by 2004.